Prime Highlights-
- Dr Martens confirms unchanged FY27 guidance ahead of annual meeting.
- Profit before tax surges 271.6 percent year on year to 32.7 million pounds.
Key Facts-
- Adjusted EBIT grew 30.6 percent to 79.3 million pounds in May.
- The USA remains Dr Martens’ largest and fastest growing market.
Background-
British footwear brand Dr Martens confirmed its full year 2027 guidance remains unchanged and on track with strategic objectives, ahead of its annual general meeting.
The company said it continues to make progress on four key strategic goals. On the consumer side, it aims to drive full price revenue mix across the UK and DACH region.
A fresh sandals line is also in the works as part of the brand’s product plansDr Martens is also eyeing fresh retail formats for major cities around the globe. Internally, the company is working to draw more value from its operating model and technology systems.
Dr Martens said its largest market, the United States, continues to grow, with wholesale performance particularly strong. The company’s largest Asian markets, Japan and South Korea, are also performing well. European markets are meeting expectations despite a challenging consumer environment across the region.
The update follows a strong set of results in May, when profit before tax rose 271.6 percent year on year to 32.7 million pounds, up from 8.8 million pounds in 2025.
Adjusted profit before tax climbed 61.3 percent to 55 million pounds during the same period, while adjusted EBIT grew 30.6 percent to 79.3 million pounds.
The steady guidance comes as Dr Martens works through its broader turnaround strategy, balancing growth in key international markets against a mixed consumer spending environment in parts of Europe.
Strength in the United States, especially in wholesale, stands as a key factor behind the company’s unchanged outlook for the year ahead.